Joy A Hessel, FNP Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 305 S Highway 27, Cadott, WI 54727 Phone: 715-289-3102 |
News Archive
Incyte Corporation today announced that its strategic collaborator, Novartis, received approval from the European Commission for Jakavi (INC424, ruxolitinib), an oral JAK 1 and JAK 2 inhibitor discovered by Incyte, for the treatment of disease-related splenomegaly or symptoms in adult patients with primary myelofibrosis (also known as chronic idiopathic myelofibrosis), post-polycythemia vera myelofibrosis or post-essential thrombocythemia myelofibrosis.
HHS Secretary Kathleen Sebelius today announced the availability of up to $335 million for existing community health centers across the country under the Expanded Services (ES) initiative. These funds are made possible by the Affordable Care Act and will increase access to preventive and primary health care, including dental health, behavioral health, pharmacy, vision, and/or enabling services, at existing health center sites.
This report from the Center for Strategic & International Studies' Global Health Policy Center, titled "Protection of Health Care in Armed and Civil Conflict," examines how "action [last year] at the U.N. Security Council, the World Health Organization, and the U.S. Department of State, combined with a new campaign by the International Committee of the Red Cross and civil society mobilization, led to potential breakthroughs in three key dimensions of protection - documentation, prevention, and accountability."
Today, the U.S. Food and Drug Administration cleared the use of the XSTAT 30 wound dressing, an expandable, multi-sponge dressing used to control severe, life-threatening bleeding from wounds in areas that a tourniquet cannot be placed (such as the groin or armpit) in battlefield and civilian trauma settings.
› Verified 5 days ago